

# Samuel

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5482530/samuel-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225  
papers

18,533  
citations

47  
h-index

135  
g-index

244  
ext. papers

22,844  
ext. citations

8.4  
avg, IF

6.85  
L-index

#	Paper	IF	Citations
225	Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e419S-e496S	5.3	2575
224	Dabigatran versus warfarin in the treatment of acute venous thromboembolism. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2342-52	59.2	1914
223	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2950-2973	15.1	1682
222	Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. <i>Circulation</i> , <b>2011</b> , 123, 1788-830	16.7	1448
221	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , <b>2020</b> , 41, 543-603	9.5	1043
220	Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. <i>Circulation</i> , <b>2014</b> , 129, 764-72	16.7	678
219	Pulmonary embolism and deep vein thrombosis. <i>Lancet, The</i> , <b>2012</b> , 379, 1835-46	40	605
218	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 752-762	59.2	538
217	A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. <i>JACC: Cardiovascular Interventions</i> , <b>2015</b> , 8, 1382-1392	5	427
216	Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2167-77	59.2	423
215	A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 259-62	3	385
214	Risk factors for venous thromboembolism. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 1-7	15.1	377
213	Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 2240-2252	59.2	363
212	Pulmonary embolism. <i>Lancet, The</i> , <b>2004</b> , 363, 1295-305	40	305
211	Echocardiography in the management of pulmonary embolism. <i>Annals of Internal Medicine</i> , <b>2002</b> , 136, 691-700	8	304
210	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 534-44	59.2	286
209	Acute pulmonary embolism: part I: epidemiology, pathophysiology, and diagnosis. <i>Circulation</i> , <b>2003</b> , 108, 2726-9	16.7	267

208	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 1620-1630	27.4	235
207	New onset of venous thromboembolism among hospitalized patients at Brigham and Women@ Hospital is caused more often by prophylaxis failure than by withholding treatment. <i>Chest</i> , <b>2000</b> , 118, 1680-4	5.3	176
206	Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. <i>Circulation</i> , <b>1995</b> , 92, 2800-216.7	16.7	158
205	Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. <i>Chest</i> , <b>2002</b> , 122, 1933-7	5.3	152
204	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1004-1024	7	147
203	A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 1401-1410	5	147
202	Venous thromboembolism: epidemiology and magnitude of the problem. <i>Best Practice and Research in Clinical Haematology</i> , <b>2012</b> , 25, 235-42	4.2	145
201	Predictive Value of Computed Tomography in Acute Pulmonary Embolism: Systematic Review and Meta-analysis. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 747-59.e2	2.4	138
200	More than an anticoagulant: Do heparins have direct anti-inflammatory effects?. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 437-444	7	121
199	Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2060-2072	15.1	119
198	Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. <i>Circulation</i> , <b>2019</b> , 139, 1162-1173	16.7	104
197	Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 1475-8	15.1	102
196	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 1198-1204	2.4	101
195	Acute pulmonary embolism: part II: risk stratification, treatment, and prevention. <i>Circulation</i> , <b>2003</b> , 108, 2834-8	16.7	101
194	Inferior Vena Cava Filters to Prevent Pulmonary Embolism: Systematic Review and Meta-Analysis. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1587-1597	15.1	94
193	Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series of 115 Patients. <i>Annals of Thoracic Surgery</i> , <b>2015</b> , 100, 1245-51; discussion 1251-2	2.7	84
192	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1903-1921	15.1	84
191	Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. <i>Circulation</i> , <b>1997</b> , 95, 577-80	16.7	78

190	The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. <i>American Heart Journal</i> , <b>2014</b> , 167, 335-41	4.9	69
189	Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. <i>American Heart Journal</i> , <b>2009</b> , 157, 1064-73	4.9	65
188	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , <b>2017</b> , 1, e56-e65	2.7	62
187	Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 1112-7	11.5	58
186	Thrombolysis for pulmonary embolism. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 1131-2	59.2	58
185	Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1999</b> , 8, 139-42	5.1	58
184	Axial and reformatted four-chamber right ventricle-to-left ventricle diameter ratios on pulmonary CT angiography as predictors of death after acute pulmonary embolism. <i>American Journal of Roentgenology</i> , <b>2012</b> , 198, 1353-60	5.4	56
183	Cardiology patient pages. Pulmonary embolism and deep vein thrombosis. <i>Circulation</i> , <b>2002</b> , 106, 1436-8	16.7	56
182	Warfarin and Vascular Calcification. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 635.e1-4	2.4	55
181	Peripheral Artery Disease: Past, Present, and Future. <i>American Journal of Medicine</i> , <b>2019</b> , 132, 1133-1141	2.4	49
180	Pulmonary embolism thrombolysis: broadening the paradigm for its administration. <i>Circulation</i> , <b>1997</b> , 96, 716-8	16.7	49
179	Vena Caval Filter Utilization and Outcomes in Pulmonary Embolism: Medicare Hospitalizations From 1999 to 2010. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1027-1035	15.1	47
178	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). <i>Circulation</i> , <b>2017</b> , 135, 648-655	16.7	46
177	Comparison of ECG-gated versus non-gated CT ventricular measurements in thirty patients with acute pulmonary embolism. <i>International Journal of Cardiovascular Imaging</i> , <b>2009</b> , 25, 101-7	2.5	46
176	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. <i>American Heart Journal</i> , <b>2017</b> , 185, 93-100	4.9	43
175	Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER <sup>I</sup> , RE-COVER <sup>II</sup> , and RE-MEDY <sup>I</sup> . <i>Vascular Medicine</i> , <b>2016</b> , 21, 506-514	3.3	43
174	Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 574-576	27.4	43
173	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , <b>2020</b> , 196, 382-394	8.2	43

172	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 319-327	7	43
171	A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). <i>Blood</i> , <b>2011</b> , 118, 205-205	2.2	41
170	Prevention of venous thromboembolism among hospitalized medical patients. <i>Circulation</i> , <b>2005</b> , 111, e1-3	16.7	38
169	Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel. <i>Vascular Medicine</i> , <b>2016</b> , 21, 400-7	3.3	35
168	Thrombolysis in Pulmonary Embolism. <i>Circulation</i> , <b>2001</b> , 104, 2876-2878	16.7	34
167	Thrombolytic therapy for patients with pulmonary embolism who are hemodynamically stable but have right ventricular dysfunction: pro. <i>Archives of Internal Medicine</i> , <b>2005</b> , 165, 2197-9; discussion 2204-5		33
166	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 33-42	35.1	31
165	Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	30
164	Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 2045-2052	7	29
163	Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 21-28	7.1	28
162	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 2046-2052	7	28
161	Cardiology patient pages. Prevention of deep vein thrombosis and pulmonary embolism. <i>Circulation</i> , <b>2004</b> , 110, e445-7	16.7	27
160	Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , <b>2020</b> , 8, 8-23.e18	3.2	27
159	Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2008</b> , 26, 35-40	5.1	26
158	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). <i>Circulation</i> , <b>2018</b> , 137, 91-94	16.7	25
157	Optimal duration of anticoagulation after venous thromboembolism. <i>Circulation</i> , <b>2011</b> , 123, 664-7	16.7	25
156	Risk factors for major bleeding in the SEATTLE II trial. <i>Vascular Medicine</i> , <b>2017</b> , 22, 44-50	3.3	24
155	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 408-411	15.1	24

154	Gastrointestinal complications of dual antiplatelet therapy. <i>Circulation</i> , <b>2006</b> , 113, e655-8	16.7	23
153	Pulmonary embolism after coronary artery bypass grafting. <i>Circulation</i> , <b>2004</b> , 109, 2712-5	16.7	23
152	Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , <b>2017</b> , 7, e014579	3	22
151	Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral-Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 633-644	7	22
150	Dementia and Atrial Fibrillation: Pathophysiological Mechanisms and Therapeutic Implications. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 1408-1417	2.4	21
149	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , <b>2021</b> ,	7	21
148	Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). <i>European Heart Journal</i> , <b>2020</b> , 41, 1086-1096	9.5	19
147	Expanding anticoagulation management services to include direct oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 274-280	5.1	19
146	Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , <b>2016</b> , 27, 787-94	2.4	19
145	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , <b>2016</b> , 129, S1-S29	2.4	19
144	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1365-1372	7	18
143	Four key questions surrounding thrombolytic therapy for submassive pulmonary embolism. <i>Vascular Medicine</i> , <b>2016</b> , 21, 47-52	3.3	18
142	Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial. <i>Vascular Medicine</i> , <b>2019</b> , 24, 442-451	3.3	18
141	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 2389-2395	7	18
140	Evaluation of a Device Combining an Inferior Vena Cava Filter and a Central Venous Catheter for Preventing Pulmonary Embolism Among Critically Ill Trauma Patients. <i>Journal of Vascular and Interventional Radiology</i> , <b>2017</b> , 28, 1248-1254	2.4	17
139	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1694-1706	15.4	17
138	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 45	5.3	17
137	Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. <i>Hospital Practice (1995)</i> , <b>2015</b> , 43, 249-57	2.2	16

136	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , <b>2018</b> , 198, 84-90	4.9	16
135	Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study. <i>International Journal of Cardiology</i> , <b>2018</b> , 268, 137-142	3.2	16
134	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 972.e1-972.e7	2.4	15
133	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1675-1685	7	15
132	Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. <i>European Heart Journal</i> , <b>2014</b> , 35, 1836-43	9.5	15
131	Venous thromboembolism risk among hospitalized patients: magnitude of the risk is staggering. <i>American Journal of Hematology</i> , <b>2007</b> , 82, 775-6	7.1	15
130	DVT Prevention: what is happening in the "real world"?. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2003</b> , 29 Suppl 1, 23-31	5.3	15
129	Prevention of recurrent idiopathic venous thromboembolism. <i>Circulation</i> , <b>2004</b> , 110, IV20-4	16.7	15
128	Treatment of pulmonary thromboembolism. <i>Internal Medicine</i> , <b>1999</b> , 38, 620-5	1.1	15
127	New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2020</b> , 6, 301-309	6.4	15
126	NOACs for treatment of venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1317-1325	7	14
125	Gender comparisons in pulmonary embolism (results from the International Cooperative Pulmonary Embolism Registry [ICOPER]). <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 616-9	3	14
124	Epidemiology of pulmonary embolism. <i>Seminars in Vascular Medicine</i> , <b>2001</b> , 1, 139-46		14
123	Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 555-561	4.5	14
122	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 1-8	5.1	14
121	Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 714-21	7	13
120	Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. <i>Vascular Medicine</i> , <b>2016</b> , 21, 361-8	3.3	13
119	Low intensity warfarin anticoagulation is safe and effective as a long-term venous thromboembolism prevention strategy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2006</b> , 21, 51-2	5.1	13

118	Deep venous thrombosis: early discharge strategies and outpatient management. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1999</b> , 7, 113-22	5.1	13
117	Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619876030	3.3	12
116	Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , <b>2013</b> , 122, 582-582	2.2	12
115	Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. <i>Intensive Care Medicine</i> , <b>2019</b> , 45, 477-487	14.5	12
114	LetQ Stop Dichotomizing Venous Thromboembolism as Provoked or Unprovoked. <i>Circulation</i> , <b>2018</b> , 138, 2591-2593	16.7	12
113	RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 415-427	7	11
112	Cardiology patient pages. Treatment of blood clots. <i>Circulation</i> , <b>2002</b> , 106, e138-40	16.7	11
111	Eradication of hospital-acquired venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2010</b> , 104, 1089-92		10
110	Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , <b>2013</b> , 122, 212-212	2.2	10
109	Syncope (Fainting). <i>Circulation</i> , <b>2016</b> , 133, e600-2	16.7	10
108	Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. <i>Oncologist</i> , <b>2021</b> , 26, e8-e16	5.7	10
107	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2016</b> , 21, 227-32	2.6	9
106	Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. <i>American Heart Journal</i> , <b>2015</b> , 169, 186-7	4.9	9
105	Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II. <i>Blood</i> , <b>2013</b> , 122, 2375-2375	2.2	9
104	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1635-1654	15.1	9
103	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 44, 457-465	5.1	8
102	Cardiology Patient Page: inflammation and myocardial infarction. <i>Circulation</i> , <b>2014</b> , 130, e334-6	16.7	8
101	Percutaneous mechanical thrombectomy for massive pulmonary embolism: improve safety and efficacy by sharing information. <i>Catheterization and Cardiovascular Interventions</i> , <b>2007</b> , 70, 807-8	2.7	8

100	How chest CT for the diagnosis of pulmonary embolism (PE) has changed my professional life: reflections from a PE doctor. <i>Seminars in Roentgenology</i> , <b>2005</b> , 40, 8-10	0.8	8
99	Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up. <i>Blood</i> , <b>2012</b> , 120, 21-21	2.2	8
98	Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE Study. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 936-945	2.4	8
97	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , <b>2020</b> , 133 Suppl 1, 1-27	2.4	7
96	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 17-2004. A 42-year-old woman with cardiac arrest several weeks after an ankle fracture. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 2281-90	59.2	7
95	Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY. <i>Blood</i> , <b>2014</b> , 124, 1544-1544	2.2	7
94	Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVERI and RE-COVERI II. <i>Blood</i> , <b>2014</b> , 124, 594-594	2.2	7
93	Quantification and Significance of Pulmonary Vascular Volume in Predicting Response to Ultrasound-Facilitated, Catheter-Directed Fibrinolysis in Acute Pulmonary Embolism (SEATTLE-3D). <i>Circulation: Cardiovascular Imaging</i> , <b>2019</b> , 12, e009903	3.9	7
92	Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 89, 953-8	7	7
91	Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. <i>TH Open</i> , <b>2017</b> , 1, e82-e91	2.7	6
90	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , <b>2018</b> , 2, e16-e24	2.7	6
89	Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. <i>Pharmaceutical Statistics</i> , <b>2017</b> , 16, 445-450	1	6
88	Peripherally inserted central catheters: bigger is not necessarily better. <i>Chest</i> , <b>2011</b> , 140, 6-7	5.3	6
87	European Atherosclerosis Society screening recommendations for lipoprotein(a) and high-sensitivity C-reactive protein: double standard or failure of evidence-based medicine?. <i>Clinical Chemistry</i> , <b>2010</b> , 56, 1544-6	5.5	6
86	Acute pulmonary embolism: risk stratification. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>2006</b> , 35, 153-6		6
85	Unsolved issues in the treatment of pulmonary embolism. <i>Thrombosis Research</i> , <b>2001</b> , 103, V245-55	8.2	6
84	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. <i>JAMA Internal Medicine</i> , <b>2019</b> , 179, 263-265	11.5	6
83	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , <b>2021</b> , 5, e24-e34		6

82	Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. <i>TH Open</i> , <b>2018</b> , 2, e33-e38	2.7	6
81	Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	5
80	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 924-936	7	5
79	Risk Stratification Model: Lower-Extremity Ultrasonography for Hospitalized Patients with Suspected Deep Vein Thrombosis. <i>Journal of General Internal Medicine</i> , <b>2018</b> , 33, 21-25	4	5
78	Similarity in Presentation and Response to Thrombolysis Among Women and Men with Pulmonary Embolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1998</b> , 5, 95-100	5.1	5
77	Prophylaxis of Venous Thrombosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2001</b> , 3, 225-235	5	5
76	Diagnosis of pulmonary embolism. <i>Clinical Cornerstone</i> , <b>2000</b> , 2, 38-46		5
75	Tissue plasminogen activator and acute pulmonary embolism. <i>Journal of Cellular Biochemistry</i> , <b>1988</b> , 38, 303-12	4.7	5
74	Selection Bias, Orthopaedic Style: Knowing What We Don't Know About Aspirin. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2020</b> , 102, 631-633	5.6	5
73	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2022886	10.4	5
72	Computed tomography angiography with pulmonary artery thrombus burden and right-to-left ventricular diameter ratio after pulmonary embolism. <i>Vascular</i> , <b>2017</b> , 25, 54-62	1.3	4
71	Catheter-directed, ultrasound-facilitated fibrinolysis in obese patients with massive and submassive pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 257-263	5.1	4
70	Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 2089-2098	15.4	4
69	Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619880008	3.3	4
68	Management of deep venous thrombosis and pulmonary embolism. <i>Clinical Cornerstone</i> , <b>2000</b> , 2, 47-58; quiz 59-64		4
67	Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , <b>2013</b> , 122, 1136-1136	2.2	4
66	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2020</b> , 46, 908-918	5.3	4
65	Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , <b>2019</b> , 139, 1234-1236	16.7	4

64	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 214-219	5.1	4
63	Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER, RE-COVERII, and RE-MEDY. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 43, 484-489	5.1	3
62	Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis in elderly patients with pulmonary embolism: A SEATTLE II sub-analysis. <i>Vascular Medicine</i> , <b>2017</b> , 22, 324-330	3.3	3
61	Predictors of Treatment Response Following Ultrasound-Facilitated Catheter-Directed Thrombolysis for Submassive and Massive Pulmonary Embolism: A SEATTLE II Substudy. <i>Circulation: Cardiovascular Interventions</i> , <b>2020</b> , 13, e008747	6	3
60	External validation of the SOX-PTS score in a prospective multicenter trial of patients with proximal deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1381-1389	15.4	3
59	Use of Prophylaxis for Prevention of Venous Thromboembolism in Patients with Isolated Foot or Ankle Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1686-1694	7.4	3
58	A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis. <i>Journal of Visualized Experiments</i> , <b>2015</b> , e52761	1.6	3
57	Outpatient venous thromboembolism: the importance of optimum prophylaxis. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2008</b> , 5, 12-3		3
56	The approach to massive pulmonary embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2000</b> , 21, 555-61	3.9	3
55	Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. <i>American Journal of Cardiology</i> , <b>2020</b> , 133, 175-178	3	3
54	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 3080-3089	15.4	3
53	Association of ABO blood group type with cardiovascular events in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 584-586	5.1	3
52	Ultrasound-facilitated, catheter-directed thrombolysis versus anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study.. <i>American Heart Journal</i> , <b>2022</b> , 251, 43-43	4.9	3
51	Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities. <i>European Heart Journal</i> , <b>2019</b> , 40, 1515-1517	9.5	2
50	How the Results of a Randomized Trial of Catheter-Directed Thrombolysis Versus Anticoagulation alone for Submassive Pulmonary Embolism Would Affect Patient and Physician Decision Making: Report of an Online Survey. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	2
49	Cardiology Patient Page. Obstructive Sleep Apnea. <i>Circulation</i> , <b>2015</b> , 132, e114-6	16.7	2
48	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. <i>Thrombosis Research</i> , <b>2020</b> , 186, 78-79	8.2	2
47	Rationale supporting an "opt-out" policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 371-4	5.1	2

46	Improving clinician performance of inpatient venous thromboembolism risk assessment and prophylaxis. <i>Hospital Practice (1995)</i> , <b>2013</b> , 41, 123-31	2.2	2
45	Diagnosis of deep venous thrombosis. <i>Clinical Cornerstone</i> , <b>2000</b> , 2, 29-37		2
44	Post-Hoc Analysis of RE-MEDYIDemonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism. <i>Blood</i> , <b>2014</b> , 124, 4270-4270	2.2	2
43	Women and Heart Attacks. <i>Circulation</i> , <b>2016</b> , 133, e428-9	16.7	2
42	Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 331-335	5.1	2
41	Antiplatelet Prescription in Atrial Fibrillation: Association with a Low Rate of Anticoagulation. <i>TH Open</i> , <b>2018</b> , 2, e229-e232	2.7	2
40	"Acute Management of High- and Intermediate-Risk Pulmonary Embolism in Children: A Review". <i>Chest</i> , <b>2021</b> ,	5.3	2
39	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021467 <sup>6</sup>		2
38	Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hip and knee Replacement (PEPPER): the PEPPER trial protocol. <i>BMJ Open</i> , <b>2022</b> , 12, e060000	3	2
37	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , <b>2019</b> , 3, e103-e108	2.7	1
36	A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2018</b> , 6, 54-61	0.9	1
35	Diagnosis. Magnetic resonance angiography and venography were sensitive but had poor technical adequacy for diagnosing pulmonary embolism. <i>Annals of Internal Medicine</i> , <b>2010</b> , 153, JC1-12	8	1
34	Pulmonary embolism in Black Americans. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 465-6	7.1	1
33	Dabigatran Etxilate Versus Warfarin in the Treatment of Venous Thromboembolism.. <i>Blood</i> , <b>2009</b> , 114, 1-1	2.2	1
32	Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy : Piazza: outcomes of high-bleeding risk AF patients. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 281-290	5.1	1
31	Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2021</b> ,	5.3	1
30	Association of Socioeconomic Disadvantage With Mortality and Readmissions Among Older Adults Hospitalized for Pulmonary Embolism in the United States. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021117	6	1
29	Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 405-412	5.1	1

28	The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. <i>Thrombosis Research</i> , <b>2021</b> , 203, 155-162	8.2	1
27	Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. <i>Circulation: Cardiovascular Imaging</i> , <b>2021</b> , 14, e012347	3.9	1
26	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 3031-3043	15.4	1
25	Women@ representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment.. <i>Contemporary Clinical Trials</i> , <b>2022</b> , 115, 106714	2.3	1
24	Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , <b>2020</b> , 19, 178-186	1.3	0
23	Pharmacomechanical Therapy for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1752-1753	59.2	0
22	Catheter-directed thrombolysis for deep vein thrombosis: 2021 update. <i>Vascular Medicine</i> , <b>2021</b> , 26, 662-669	3.3	0
21	Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , <b>2021</b> , 20, 103-107	1.3	0
20	PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients. <i>BMJ Open</i> , <b>2021</b> , 11, e041845	3	0
19	Stroke risk factors and outcomes among hospitalized women with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 1023-1031	5.1	0
18	Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 1	5.1	0
17	Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study.. <i>Thrombosis Research</i> , <b>2022</b> , 214, 122-131	8.2	0
16	Heparin-Induced Thrombocytopenia in Healthy Individuals with Continuous Heparin Infusion. <i>TH Open</i> , <b>2018</b> , 2, e49-e53	2.7	
15	Thromboprophylaxis Strategies in Acute Medically Ill Patients. <i>Current Emergency and Hospital Medicine Reports</i> , <b>2019</b> , 7, 118-126	0.9	
14	Venous thromboembolism: "... an ounce of prevention is worth a pound of cure". <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 1174-5	7	
13	Deep Venous Thrombosis: Early Discharge Strategies and Outpatient Management. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1997</b> , 4, 365-374	5.1	
12	Possible requiem: trial-and-error warfarin. <i>Blood</i> , <b>2007</b> , 110, 1404-1405	2.2	
11	Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial.. <i>Thrombosis Research</i> , <b>2022</b> , 211, 63-69	8.2	

10	Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER I and RE-COVER II <i>Blood</i> , <b>2015</b> , 126, 4730-4730	2.2
9	The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial. <i>Blood</i> , <b>2016</b> , 128, 3824-3824	2.2
8	Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 158-160	5.1
7	Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 22-29	5.1
6	Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 561-570	5.1
5	Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2021</b> , 27, 10760296211037920	3.3
4	Images in Vascular Medicine: Pulmonary embolism and acute aortic syndromes - Double trouble when vascular medicine emergencies meet. <i>Vascular Medicine</i> , <b>2021</b> , 1358863X211029695	3.3
3	Impact of Atrial Fibrillation on In-Hospital Mortality and Stroke in Acute Aortic Syndromes. <i>American Journal of Medicine</i> , <b>2021</b> , 134, 1419-1423	2.4
2	Pulmonary embolism diagnosis: remember the history and physical exam. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 101, 7-8	7
1	Do take that break. <i>Harvard Business Review</i> , <b>2009</b> , 87, 30, 128	